Evolution of the Average Target: Valneva SE

Evolution of the Target Price: Valneva SE

Changes in Analyst Recommendations: Valneva SE

cd84b0945df841e967.cTLOE8G42KQlCQSz5LBV2C2kX0AEgERum5yZr3t36-k.EkSDS6Xa4cBJbzL5rv4Fv0LcLzBN3xYGrNrO5ywunIYnaqVy-e717B19cw~6855b98e39d61cc1f1f8acf53a82d388
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
03/09/25 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
26/08/25 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
26/08/25 Valneva: Stifel adjusts target price Zonebourse
12/08/25 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
14/07/25 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
13/08/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24/06/24 Valneva rises after Canadian approval for its chikungunya vaccine RE
05/02/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
02/01/24 Valneva: Oddo BHF remains positive Zonebourse
10/11/23 HC Wainwright Adjusts Price Target on Valneva SE to $26 From $22, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+137.23%
+14.91%
+8.27%
+10.95%
+35.32%
+48.53%
+13.4%
-13.54%
+2.94%
+7.87%
Average +26.59%
Weighted average by Cap. +17.10%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.206EUR
Average target price
5.233EUR
Spread / Average Target
+137.23%
High Price Target
7.500EUR
Spread / Highest target
+239.98%
Low Price Target
2.100EUR
Spread / Lowest Target
-4.81%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
HC Wainwright
Kepler Cheuvreux
Guggenheim
Jefferies & Co.
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.206EUR
Average target price
5.233EUR
Spread / Average Target
+137.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. Consensus Valneva SE